Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
The observation that neural grafts can induce dyskinesias has severely hindered the development of a transplantation therapy for Parkinson's disease (PD). We addressed the hypothesis that inflammatory responses within and around an intrastriatal graft containing dopamine neurons can trigger dyskinetic behaviors. We subjected rats to unilateral nigrostriatal lesions with 6-hydroxydopamine (6-OHDA) and treated them with L-DOPA for 21 days in order to induce abnormal involuntary movements (AIMs). Subsequently, we grafted the rats with allogeneic embryonic ventral mesencephalic tissue in the dopamine-denervated striatum. In agreement with earlier studies, the grafted rats developed dyskinesia-like AIMs in response to amphetamine. We then used two experimental approaches to induce an inflammatory response and examined if the amphetamine-induced AIMs worsened or if spontaneous AIMs developed. In one experiment, we challenged the neural graft hosts immunologically with an orthotopic skin allograft of the same genetic origin as the intracerebral neural allograft. In another experiment, we infused the pro-inflammatory cytokine interleukin 2 (IL-2) adjacent to the intrastriatal grafts using osmotic minipumps. The skin allograft induced rapid rejection of the mesencephalic allografts, leading to disappearance of the amphetamine-induced AIMs. Contrary to our hypothesis, the rejection process itself did not elicit AIMs. Likewise, the IL-2 infusion did not induce spontaneous AIMs, nor did it alter L-DOPA-induced AIMs. The IL-2 infusions did, however, elicit the predicted marked striatal inflammation, as evidenced by the presence of activated microglia and IL2Ralpha-positive cells. These results indicate that an inflammatory response in and around grafted dopaminergic neurons is not sufficient to evoke dyskinetic behaviors in experimental models of PD.
Lane
E L
EL
Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Sweden. laneel@Cardiff.ac.uk
Soulet
D
D
Vercammen
L
L
Cenci
M A
MA
Brundin
P
P
D018663:Adrenergic Agents / Q000633:toxicity; D000661:Amphetamine / Q000494:pharmacology; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage; D000704:Analysis of Variance; D000818:Animals; D000978:Antiparkinson Agents; D016380:Brain Tissue Transplantation / Q000009:adverse effects* / Q000276:immunology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D003342:Corpus Striatum / Q000637:transplantation; D004195:Disease Models, Animal; D020820:Dyskinesias / Q000209:etiology* / Q000378:metabolism*; D004622:Embryo, Mammalian; D004660:Encephalitis / Q000209:etiology*; D005260:Female; D007376:Interleukin-2 / Q000009:adverse effects; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D007980:Levodopa / Q000009:adverse effects; D008636:Mesencephalon / Q000601:surgery; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000188:drug therapy / Q000209:etiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D016038:Skin Transplantation
D018663:Adrenergic Agents; D018712:Analgesics, Non-Narcotic; D000978:Antiparkinson Agents; D000697:Central Nervous System Stimulants; D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit; D007980:Levodopa; D016627:Oxidopamine; D000661:Amphetamine